Acute promyelocytic leukemia
MONDO:0012883An aggressive form of acute myeloid leukemia (AML), characterized by arrest of leukocyte differentiation at the promyelocyte stage, due to a specific chromosomal translocation t(15;17) in myeloid cells. APL manifests with easy bruising, hemorrhagic diathesis and fatigue.
Also known as: AML M3, AML with t(15;17)(q22;q12), AML with t(15;17)(q22;q12);(PML/RARalpha) and variants, APL, APML, APML - acute promyelocytic leukaemia, APML - acute promyelocytic leukemia, FAB M3
3099 clinical trials for this condition and its sub-types, 20 tagged with Acute promyelocytic leukemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New strategy cuts early deaths in rare leukemia
Disease control OngoingThis study tested a simplified care plan for people with acute promyelocytic leukemia (APL), a rare blood cancer. The goal was to see if following easy-to-use guidelines and getting support from APL experts could lower the number of deaths soon after starting treatment. About 200…
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Precision radiation may boost stem cell transplant success in tough leukemias
Disease control OngoingThis study tests a precise radiation method called total marrow and lymphoid irradiation (TMLI) given with two chemotherapy drugs (etoposide and cyclophosphamide) before a donor stem cell transplant. The goal is to safely deliver higher radiation doses to the bone marrow to wipe …
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Arsenic and vitamin a derivative may replace harsh chemo for leukemia
Disease control OngoingThis phase III trial tests a combination of arsenic trioxide and tretinoin (a vitamin A derivative) in 158 people with newly diagnosed acute promyelocytic leukemia (APL). The goal is to see if this drug pair can replace high-dose anthracycline chemotherapy, which can cause long-t…
Phase 3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New cocktail aims to tame dangerous leukemia in High-Risk patients
Disease control OngoingThis study tests whether adding venetoclax to the standard two-drug regimen (ATRA and arsenic trioxide) can help patients with a rare blood cancer called acute promyelocytic leukemia (APL) who have very high white blood cell counts. These patients often face serious complications…
Sponsor: Anhui Medical University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC